Search Results

You are looking at 221 - 230 of 460 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Andrew H. Ko and Christopher H. Crane

relative importance of chemotherapy and radiation as adjuvant therapy ( Table 1 ). The ESPAC-1 trial, 2 conducted by the European Study Group for Pancreatic Cancer, used a 2-by-2 factorial design in which patients were randomly assigned after surgery to 1

Full access

Eric H. Bent, Eric Wehrenberg-Klee, Eugene J. Koay, Lipika Goyal, and Jennifer Y. Wo

individually been evaluated in the neoadjuvant and adjuvant settings with mixed results. 74 – 77 At this time, the guidelines of the AASLD and the European Association for the Study of the Liver do not recommend neoadjuvant or adjuvant therapy in most patients

Full access

Robert B. Hines, Alina Barrett, Philip Twumasi-Ankrah, Dominique Broccoli, Kimberly K. Engelman, Joaquina Baranda, Elizabeth A. Ablah, Lisette Jacobson, Michelle Redmond, Wei Tu, and Tracie C. Collins

and the decreasing likelihood of receiving neoadjuvant/adjuvant therapy. 42 , 43 , 47 A reason for these findings has been the increasing prevalence of comorbid disease in older age groups. Consistent with the literature, 10 , 38 , 42 , 43 , 47 – 52

Full access

Elizabeth R. Kessler, Janet B. Kukreja, Christopher L. Geiger, and Stacy M. Fischer

toxicity calculator, then they may opt for surgical resection and discussion of the role of adjuvant therapy based on the pathologic risk identified at the time of surgery. Table 2. Criteria for Cisplatin Ineligibility For patients who do not receive NAC

Full access

risks of postsurgical complications. 5 “How we thought about adjuvant therapy has changed,” said Dr. Gradishar. “Physicians used to look at the number of nodes as a determinant of whether a patient was a candidate for chemotherapy, as well as what kind

Full access

Dawn J. Brooks

, 2015 . 2. Berry DA Cronin KA Plevritis SK Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators . Effect of screening and adjuvant therapy on mortality from breast cancer . N Engl J Med 2005 ; 353 : 1784 – 1792

Full access

Bruce Brockstein, Mario Lacouture, and Mark Agulnik

Edited by Kerrin G. Robinson

(CRT) followed by G adjuvant therapy for locally advanced head and neck cancer (HNC) [abstract] . J Clin Oncol 2007 ; 25 ( Suppl 1 ): Abstract 6028 . 59. Herchenhorn D Dias FL Pineda RM . Phase II study of erlotinib combined with

Full access

Matt Brow, J. Russell Hoverman, Debra Patt, Bill Herman, Diana Verrilli, Jody Garey, and Roy Beveridge

support (and your adopted pathway for any given instance) when it really matters—at the point of decision—can be expensive. Agreement on common definitions can also be difficult, even for elements as simple as what constitutes third-line or adjuvant

Full access

Borislav Hristov, Ori Shokek, and Deborah A. Frassica

curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orth Rel Res 2005 ; 435 : 211 – 218 . 49. Chen ZX Gu DZ Yu ZH . Radiation therapy of giant cell tumor of bone: analysis of 35 patients . Int J

Full access

Scott M. Schuetze

. Adjuvant therapy of osteosarcoma—a phase II trial: Southwest Oncology Group study 9139 . Cancer 2004 ; 100 : 818 – 825 . 33. Voute PA Souhami RL Nooij M . A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial